TSW
CLBT icon

Thompson Siegel & Walmsley’s Cellebrite CLBT Stock Holding History

Thompson Siegel & Walmsley’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-39,062
Closed -$199K – 559
2022
Q2 		$199K Buy
39,062
+5,000
+15% +$26K ﹤0.01% 347
2022
Q1 		$218K Buy
+34,062
New +$226K ﹤0.01% 371

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
LSCM
Light Street Capital Management Palo Alto, California $903M AUM 113.12% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
IP
Isomer Partners New York $74.3M AUM 23.95% 1-Year Est. Return
CC
Crosslink Capital Menlo Park, California $1.35B AUM 35.86% 1-Year Est. Return
CIBC Asset Management
CIBC Asset Management Toronto, Ontario, Canada $45.6B AUM 44.74% 1-Year Est. Return
MCM
Makena Capital Management Menlo Park, California $952M AUM 13.93% 1-Year Est. Return
CPM
Crescent Park Management East Palo Alto, California $40.5M AUM 5.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Thompson Siegel & Walmsley's CLBT Position: Q3 2022 in Review

Thompson Siegel & Walmsley sold out of Cellebrite (CLBT) in Q3 2022, closing a stake of 39,062 shares — an estimated $199K sold.

Thompson Siegel & Walmsley first reported a position in CLBT in Q1 2022 and held it in 2 quarters. The position peaked at $218K in Q1 2022. 44 funds tracked by Wall St. Rank hold CLBT as of Q3 2022.

  • Thompson Siegel & Walmsley reported no remaining Cellebrite position as of Q3 2022 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 39,062 Cellebrite shares in Q3 2022, an estimated $199K.
  • Thompson Siegel & Walmsley first reported a position in Cellebrite in Q1 2022 and held it in 2 quarters.
  • Thompson Siegel & Walmsley's Cellebrite position peaked at $218K in Q1 2022.
  • 44 funds tracked by Wall St. Rank held Cellebrite as of Q3 2022.

Based on Thompson Siegel & Walmsley's 13F filing for Q3 2022, filed 25 Oct 2022.